Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK233705 plus salmeterol vs salmeterol, tiotropium and placebo in COPD
2006-003500-19Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of darotropium bromide in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by GSK. Primary endpoint: Morning trough FEV1 on Day 8. Started Aug 2006; status: completed.
02
Drugs
darotropium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-003500-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003500-19.